ABBOTT LABORATORIES WKN: 850103 ISIN: US0028241000 Kürzel: ABT Forum: Aktien Thema: Hauptdiskussion

https://www.diepresse.com/18707239/unreine-babynahrung-abbott-muss-95-millionen-dollar-zahlen Das könnte den Kurs kurzfristig weiter belasten

Hat sicher aber schnell wieder erholt 🤠

Echt stark heute dieses Momentum

Erwartungen übertroffen, Jahresprognose angehoben, Kurs sinkt 😂 Börse…

Positiv: Total Q2 2024 sales of $10.4 billion, a 4.0% increase. Organic sales growth of 9.3%. GAAP diluted EPS of $0.74; adjusted EPS of $1.14. Raised full-year 2024 EPS guidance to $3.30-$3.40 (GAAP) and $4.61-$4.71 (adjusted). FDA approval for Esprit™ BTK and two new continuous glucose monitoring systems. CE Mark for AVEIR® dual chamber leadless pacemaker. Medical Devices sales increased by 10.2%, with 12.1% organic growth. Diabetes Care sales up 18.4% reported and 20.4% organically. 10 new growth opportunities from R&D pipeline in H1 2024.

- Second-quarter GAAP diluted EPS of $0.74 and adjusted diluted EPS of $1.14, which excludes specified items. - Sales of $10.4 billion - Abbott raised its full-year 2024 EPS guidance range. Abbott projects full-year diluted EPS on a GAAP basis of $3.30 to $3.40 and projects adjusted diluted EPS of $4.61 to $4.71. "We achieved another quarter of strong growth in our underlying base business," said Robert B. Ford, chairman and chief executive officer, Abbott. "We have a lot of positive momentum heading into the second half of the year and are raising our full-year guidance."

Abbott Laboratories Q2 2024 Adj EPS $1.14 Beats $1.10 Estimate, Sales $10.377B Beat $10.371B Estimate

Unterstützung hält. Falls der Markt da jetzt nicht total verrückt spielt ist hier eine super kaufgelegenheit

Mal sehen wo der Kurs heute Abend steht. Die Hälfte des Verlusts ist dann vermutlich schon wieder aufgeholt.

Aussichten begeistern nicht gerade. Aber ich finde den Kursrutsch auch übertrieben.

Aber warum ist es runtergegangen,m

gute zahlen passt weitermachen

$ABT | Abbott Laboratories Q1 Earnings Highlights: 🔹 Adj. EPS: $0.98 (Est. $0.95) 🟢 🔹 Revenue: $9.96B (Est. $9.89B) 🟡 🔹 Organic Sales Growth in Q1: Up 4.7% Narrowed Guidance: 🔹 FY'24 Adj. EPS: $4.55 to $4.70 (Prev. $4.50 to $4.70, Est. $4.62) 🟡 🔹 FY'24 GAAP EPS: $3.25 to $3.40 🔸 Q2'24 Adj. EPS: $1.08 to $1.12 (Est. $1.12) 🔴 Operational Highlights: 🔹 FY 2024 Organic Sales Growth Forecast: 8.5% to 10% (Excluding COVID-19 related sales) Key Metrics and Updates: 🔹 Adjusted Net Debt to EBITDAR: 2.7x 🔹 Specified Items Impact (mostly amortization, restructuring): $1.30 per share for FY Strategic Developments: 🔸 Raised the midpoint of full-year guidance ranges, reflecting confidence in ongoing business performance. 🔸 Noted strong performance particularly in medical device sales contributing to earnings beat.

Na dann schau dir mal die heutige Kursentwicklung von Reckitt Benkiser. Betrifft dasselbe Gerichtsurteil. Da ist das hier ja ein Ponyhof dagegen.